Recursion Pharmaceuticals Stock
Automated drug discovery platform
Sign up today and learn more about Recursion Pharmaceuticals Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Recursion Pharmaceuticals Stock
Recursion Pharmaceuticals is an automated drug discovery platform. The company combines experimental biology, automation, and artificial intelligence in a parallel system that aims to efficiently identify treatments for any disease which can be modeled at the cellular level. The company uses computer vision to study images of how diseases affect healthy cells and claims to have put together the largest biological image set in the world, as it tracks almost half a million experiments a week.
Recursion Pharmaceuticals has broadened its platform to probe data from automated screens for a number of indications, including aging, inflammation, infectious disease, and immunology. While the company tries to make its own drugs for rare discoveries, it has also sought partnerships with major pharmaceutical companies like Sanofi and Takeda, on other rare diseases, hoping to tackle oncology and inflammation.
The company is headquartered in Salt Lake City, Utah and was founded by Blake Borgeson, Chris Gibson, and Dean Li in 2013.
Co-Founder and Chief Executive Officer
Senior Vice President of Translational Discovery & Chief Evangelist
Vice President, Intellectual Property
Senior Vice President of Biology
Vice President of Chemistry
Vice President, Data Science
Vice President of Finance
Chief Scientific Officer
Vice President of Business Development & Corporate Initiatives
Chief People Officer
President and Chief Operating Officer
Vice President, Core Operations
Vice President of Engineering
Vice President of Project Management & Chief of Staff
Chief Technology Officer & Chief Product Officer